Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, announced its financial results for the fourth quarter and full-year ended December 31, 2025. The company reported a total revenue of $134.0 million for the year, reflecting a 14% increase compared to $117.3 million in 2024. This growth was driven by strong performance in product revenue, which amounted to $115.2 million, up from $115.8 million in the previous year. The fourth quarter alone saw revenue of $32.4 million, a 3% increase year-over-year.

Xtant Medical achieved a gross margin of 62.9% for the full year, compared to 58.2% in 2024, indicating improved operational efficiency. The company also reported a net income of $5.0 million for the year, a significant turnaround from a net loss of $16.5 million in 2024. This positive shift was attributed to effective cost management and strategic investments in their core biologics business.

In addition to financial growth, Xtant Medical highlighted its successful divestiture of non-core assets, which generated $21.4 million in cash. The company ended the year with $17.3 million in cash and cash equivalents, bolstered by an additional $10.5 million received in early 2026 from the divestiture.

Looking ahead, Xtant Medical anticipates full-year 2026 revenue to be in the range of $95 million to $99 million, reflecting continued organic growth in its higher-margin biologics business. The company plans to invest further in its commercial team to enhance its market presence and capitalize on its innovative product offerings. CEO Sean Browne expressed optimism about the company's trajectory, emphasizing the importance of their strengthened financial position and operational focus.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.